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Abstract
We demonstrated previously that loss of in vitro
transformation and in vivo tumorigenicity in two
independent revertant clones of HeLa cells (designated
HA and HF) resulted from dominant-acting genetic
changes. Analysis of the p53 tumor suppressor gene
revealed stabilization and at least partial restoration of
wild-type p53 transactivation properties pathways in
both revertants of HPV-induced cell transformation.
The half-lives of the p53 protein and both of the HA
and HF clones were increased ;4 fold compared with
the parental HeLa cells (16, 17, and 4 min,
respectively). The levels of E6 viral protein expression
were similar in the three cell lines, whereas the levels
of the ubiquitin ligase protein, E6 associated protein
(E6-AP), were elevated in the revertants. Western blot
analysis of immunoaffinity-purified p53 demonstrated
that stabilization of p53 in the revertants was
correlated with a reduction in the in vivo formation of
complexes involving the E6 oncoprotein and p53.
Stabilization of p53 function in the revertants did not
result from mutations in either the p53 or E6-AP genes.
Despite the observed stabilization and restoration of
p53 transactivation function in the revertants, exposure
of the revertants to DNA-damaging agents did not
result in elevated levels of p21
waf-1 protein and failed to
induce growth arrest in the G1 phase of the cell cycle.
However, p53-independent induction of p21
waf-1 protein
also failed to induce the G1 phase of the cell cycle.
Thus, restoration of wild-type p53 transactivation
activity in the HA and HF revertants is insufficient to
induce G1 arrest and reversion from HPV-induced cell
transformation in our model system.
Introduction
Cervical carcinoma is the second most common gynecolog-
ical cancer, annually claiming about 500,000 lives worldwide.
Nonproductive infection by the “high risk” HPVs types 16,
18, 31, 33, and 39, with consequent unregulated expression
of the E6 and E7 transforming viral oncogenes, has been
implicated in .90% of all cervical carcinomas (1).
It was demonstrated that high-risk HPV E6 and E7 onco-
genes, respectively, have high affinities for binding to the p53
and Rb tumor suppressor gene products and result in inac-
tivation of their functions (2). E7, like SV40 large T and
adenovirus E1A proteins, inhibits the negative regulatory ef-
fect of Rb
5 on transcription factor E2F. E6, like adenovirus
E1B and SV40 large T antigen, inhibits the transcription
transactivation and cell cycle regulatory functions of p53 (3,
4). Cervical carcinomas that do not carry an integrated high-
risk HPV genome invariably harbor inactivating mutations in
the Rb and p53 tumor suppressor genes.
Of these two tumor suppressor genes targeted by HPVs,
p53 mutation is the most commonly reported change in
human oncogenesis (5). Wild-type p53 has distinct DNA
binding and transcription factor properties (6). The p53 pro-
tein levels and DNA binding activity are inducible by DNA-
damaging agents such as actinomycin D and g-irradiation.
Induction of p53 is followed by the transcriptional activation
of genes involved in DNA repair (7–9). Wild-type p53 also
blocks cell cycle progression when it is overexpressed or in
response to DNA damage (10) and has been implicated in
apoptosis (11). Mutation or inactivation by viral oncogenes
inhibit the transactivation function of p53 and affect its phys-
iological effects on cell growth, cell cycle progression, and
apoptosis (11, 12). The major mechanism of control of p53
expression appears to be through protein stability (post-
translational modification), and several observations have
supported the hypothesis that HPV E6 modulates p53 func-
tion by targeting the protein for ubiquitination and rapid
degradation (13).
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of two independent, clonal, nontumorigenic variants of the
HeLa cervical carcinoma cell line (ATCC CCL2) after expo-
sure to the mutagen ethylmethanesulfonate (14). When com-
pared with parental HeLa cells, the HA and HF revertants
show reduced clonogenicity in semisolid medium and fail to
induce s.c. tumors upon injection in nude mice. Furthermore,
ectopic overexpression of E6, E7, or both oncogenes failed
to retransform HA or HF, excluding the possibility that rever-
sion resulted from mutations within the HPV oncogenes.
Somatic cell fusion experiments between HeLa and each of
the revertants demonstrated that in both clones, the rever-
tant phenotype resulted from the activation of one or more
endogenous tumor suppressor genes.
In the present study, we investigated the status and func-
tion of p53 tumor suppressor protein in revertant cells. The
results demonstrated that increased levels of wild-type p53
protein expression in the revertants resulted from protein
stabilization. Stabilization of p53 in the revertants resulted
from decreased formation of protein complexes between the
viral E6 oncoprotein and p53, despite the presence of high
levels of functional E6 protein expression in all cell lines.
Previous studies have shown that high affinity binding of E6
to p53 requires the presence of E6-AP (15). E6-AP is E3
ligase that triggers multi-ubiquitination and subsequent deg-
radation of p53, and the interaction of E6, E6-AP, and p53
has been demonstrated in vitro (16). We therefore examined
the revertants for altered expression or mutations in E6-AP.
The results indicated that the E6-AP was wild-type in both
revertants and that expression of the protein was actually
increased in revertants relative to HeLa cells.
In studies using a dominant-negative form of E6-AP, it was
recently shown that E6-AP is also involved in p53 degrada-
tion in vivo (17). Other in vivo studies found that inhibition of
E6-AP expression by antisense oligonucleotide results in an
increased level of p53 protein expression only in cells in-
fected with “high risk” HPV (18). These findings suggested
that stabilization of p53 might be sufficient to inhibit high-risk
HPV-induced cell transformation. To determine whether p53
was in fact contributing to the phenotypic reversion of HA
and HF cells, we examined the expression of p21
waf-1,a
direct target of the p53 transcriptional transactivation in vivo.
Unexpectedly, our results indicated that the revertants did
not express elevated levels of the p21
waf-1 protein. Although
exposure of cells to DNA-damaging agents did induce
p21
waf-1 mRNA levels in the revertants, the levels of p21
waf-1
protein remained unchanged and comparable with those in
HeLa cells. As expected from the failure to induce p21
waf-1,
DNA damage failed to induce cell cycle arrest in the revertant
cells. Moreover, induction of p21
waf-1 protein expression in
the revertants with L-mimosine also failed to arrest cells in the
G1 phase of the cell cycle. Thus, stabilization and restoration
of wild-type p53-mediated transactivation is not sufficient to
induce cell cycle arrest or reversion from the HPV-induced
cell transformed phenotype. In addition, the p21
waf-1 path-
way is not involved in reversion of the transformed pheno-
type of HeLa cells.
Results
Steady-State p53 Protein Levels Are Increased in Rever-
tants as Compared with HeLa Cells. Consistent with the
hypothesis that the p53 protein cell is targeted for rapid
degradation by HPV-18 E6, the level of p53 protein in HeLa
cells was found to be very low, whereas p53 mRNA levels
were comparable with those seen in primary cells (19). We
compared steady-state p53 protein levels in parental HeLa
and revertant cells by Western and Northern blotting (Fig. 1).
The p53 protein levels in both revertants were consistently
higher than levels seen in HeLa cells for any given set of
growth conditions (Fig. 1A). Laser densitometric analysis of
the autoradiograms from four independent experiments
showed that the p53 protein levels in the revertants were on
average ;5-fold higher than in HeLa cells. Comparable re-
sults were obtained when cell number rather than total pro-
tein was used to normalize cell extracts from the three cell
lines prior to Western blotting (not shown). Similar differ-
ences in p53 levels were found using nuclear extracts and
total cell lysate, suggesting that p53 is accumulated in nuclei.
Thus, relative to parental HeLa cells, both revertants ex-
pressed elevated steady-state levels of p53 protein, whereas
the steady-state levels of mRNA were comparable in all three
cell lines (Fig. 1B). These observations suggested an alter-
ation in posttranslational regulation of the p53 protein in the
both the HA and HF revertant clones.
The p53 and E6-AP Genes Are Wild-Type in the Rever-
tants. An increase in the p53 protein half-life has been as-
sociated with a variety of point mutations that induce either
a loss of the growth-suppressing functions or a gain in
growth-promoting functions of p53 (6). It was thus necessary
to determine the mutational status of the p53 gene in each
revertant. To demonstrate that the p53 genes expressed in
the revertants were wild type, p53 mRNA from HeLa and
revertant cells was analyzed by RNase protection assays
(Ambion Inc., Austin, TX). We also sequenced exons 4 to 11
Fig. 1. Wild-type p53 protein levels are higher in the HA and HF rever-
tants compared with parental HeLa cells, but p53 mRNA levels remain
unchanged. A, 25 mg of nuclear extract protein were separated by SDS-
PAGE. The p53 protein was detected by Western blot with p53-specific
antibody (DO-1) and a horseradish peroxidase-conjugated secondary
antibody and chemoluminescence. B, Northern blot analysis of total RNA
extracted from HeLa (H), HA (A), HF (F), and Saos-2 (S) cells. The filter was
probed with
32P-labeled p53 cDNA. C, ethidium bromide-stained filter
used for Northern blot analysis.
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prepared from revertant and HeLa cell mRNA. These exons
include the regulatory and DNA-binding regions of the p53
protein and contain .90% of the mutations observed in
human tumors. No mutations were detected within p53
cDNA using either approach (not shown). These results sug-
gested increased expression of wild-type p53 protein in both
the HA and HF revertants.
Previous studies have shown that the region of E6-AP
protein between amino acid 280 to amino acid 865 is nec-
essary and sufficient for interaction with E6 and p53 proteins
and the subsequent ubiquitination of the p53 (20). We thus
performed cDNA sequencing of this region of the E6-AP
gene in all three cell lines. The results failed to detect any
mutations within this region of E6-AP in either of the rever-
tants or in HeLa cells (data not shown). Thus, both p53 and
the functional region of the E6-AP genes are wild type in the
HA and HF revertant cell lines.
The Half-Life of p53 Is Increased in Revertants. Studies
have shown that the HPV E6 protein targets p53 for degra-
dation (15) via the ubiquitin-mediated proteosome pathway.
The results presented above were consistent with restoration
of p53 protein levels in the revertants to physiological levels.
We therefore investigated whether the p53 in the revertants
had increased stability relative to that of parental HeLa cells.
To estimate the half-life of p53, HeLa, HA, and HF, cell
lysates were prepared before and at 15, 30, and 50 or 60 min
after exposure to CHX (21). Levels of p53 protein in untreated
and CHX-treated cell lysates were determined by quantita-
tive analyses of Western blots (Fig. 2A). Regression analysis
revealed that the half-life of the p53 protein in both revertants
was at least 4-fold longer than in HeLa cells (HA, 16 min; HF,
17 min; HeLa, 4 min; Fig. 2B). Similar results were obtained
using [
35S]methionine pulse-chase experiments (not shown).
Thus, in both revertants, increased levels of p53 protein
resulted from stabilization of the p53 protein.
Interruption of E6-p53 Binding in the Revertants. The
interaction of p53 with E6 has not been documented previ-
ously in vivo. Technical problems that make this interaction
difficult to detect include the low abundance of E6 and p53
in cervical carcinoma cells with HPV integrations and the
transient nature of the interaction. We compared levels of E6
protein expression in cell lines. We detected the very similar
levels of E6 HPV protein in all cell lines using a combination
of immunoprecipitation and immunoblotting (Fig. 3A). As-
suming that a large amount of starting material is an impor-
tant prerequisite for detection of E6-p53 interaction, we used
2, 10, and 20 mg of total protein from each cell line for
immunoaffinity purification of p53. Small portions of each
column eluate were used to confirm purification of p53 (Fig.
3B). Column eluate was concentrated, and proteins were
separated on 15% SDS gel. Western blot analysis was per-
Fig. 2. The half-life of the p53 protein in revertants is increased 4-fold
over that seen in the parental HeLa cells. A, a representative Western blot
analysis of cellular lysates from HeLa, HA, and HF at various intervals after
treatment with the inhibitor of protein synthesis CHX and probed with
anti-p53 antibody (DO-1). B, quantitative analysis of Western blots by
laser densitometry. The average densitometric values from three inde-
pendent experiments were plotted as a percentage of p53 remaining as a
function of time after CHX treatment. The p53 half-life for each cell line
was calculated using the regression equation. j, HeLa, M, HA, {, HF.
Fig. 3. Reduced binding activity of E6 protein to p53 in revertants. A,
detection of E6 protein in HeLa and revertants. E6 protein was immuno-
precipitated and loaded with 15% SDS-PAGE. Antibody C1P5 were used
for detection of E6 protein in immunoprecipitates by Western blot. The
membrane was cut on the level of Mr 26,000 corresponding position of
immunoglobulin light chain. B, 20 mg of total protein from each cell line
were immunopurified on a column with attached p53-specific antibody
(1801). Less than 10% of eluate from each cell line was loaded on 10%
gel, and p53 protein was detected using Western blot. The rest of the
column eluate was concentrated and loaded on 15% gel (C). E6 protein
was detected using same antibody as in A.
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detected the Mr 18,000 E6 protein in p53 immunocomplexes
isolated from HeLa cells (Fig. 3C). In contrast, the E6 protein
band was below the detection limit in p53 immunoisolates
from the HA and HF revertants, despite the fact that p53
levels were higher in these preparations (Fig. 3B). We ob-
tained similar results from an independent experiment using
10 mg of starting material. However, we failed to detect E6
HPV protein using 2 mg of total protein, suggesting that the
amount of starting material is very important.
An immunoreactive protein with a molecular weight of Mr
;27,000 was present in every cell line, including Saos-2, and
probably corresponds to a small quantity of immunoglobulin
light chain that leached from the affinity column during sam-
ple elution. The immunoglobulin protein was only detected
when using long X-ray film exposure times for E6 detection
(35 min) but was not detectable when using shorter film
exposure for p53 detection (,30 s). These results demon-
strated that in both the HA and HF revertants, the levels of
HPV 18-E6 oncoprotein are very similar. However, the
steady-state level of complexes, including the E6 protein and
the p53 suppressor protein, was significantly reduced in both
revertants relative to levels in the parental HeLa cells.
Steady-State Levels of E6-AP Protein Are Elevated in
Revertants. E6-AP is essential for degradation of p53 in
HPV-positive cells. E6-AP also appears to be necessary for
high-affinity binding of the viral E6 oncoprotein to p53 and for
ubiquitination of p53 (13, 16). To determine whether reduced
expression of E6-AP contributed to the decreased stability of
complexes with E6, and stabilization of p53 in the revertants
resulted, we compared the expression of E6-AP among the
cell lines. The results of Northern blot analyses indicated that
the steady-state levels of E6-AP mRNA were comparable in
all cell lines (Fig. 4, A and B). However, a comparison of the
protein levels by Western blotting revealed increased steady-
state levels of E6-AP protein in the revertants compared with
HeLa cells (Fig. 4C). These results suggest that E6-AP is not
a limiting factor for p53 degradation in the cells, and expres-
sion of E6-AP in the revertants was increased by a post-
translational mechanism.
Induction of p53 by Actinomycin D in Revertants. Dis-
ruption of E6 interaction with p53 and accumulation of p53
protein in nuclei suggested restoration of wild-type proper-
ties of p53 in both revertants. Wild-type p53 protein is sta-
bilized in response to a wide range of stimuli, including
exposure to DNA-damaging agents (7). We examined the
response of HeLa and revertant cells to treatment with acti-
nomycin D and irradiation (not shown). Consistent with the
presence of wild-type p53 in HeLa cells, continuous expo-
sure of these cells to actinomycin D resulted in elevated
levels of p53 protein (Fig. 5). However, in HeLa cells, p53
declined between 12 and 24 h after exposure, whereas in
both revertants, induction of p53 protein was observed for up
to 24 h after exposure. The p53 protein continued to accu-
mulate in HA and HF at rates that were 18- and 13-fold faster,
respectively, than in HeLa cells. After 24 h of exposure to
actinomycin D, p53 protein in the revertants exceeded that in
the treated HeLa cells by 5–10-fold, comparable with those
detected in control FS4 normal human foreskin fibroblasts
(Fig. 5). Induction of p53 was attributable to posttranslational
mechanism, because no induction of p53 mRNA levels were
observed in any of the cell lines after actinomycin D treat-
ment (data not shown).
Elevated p53-induced Promoter Transactivation in the
Revertants as Compared with HeLa Cells. We next deter-
mined whether the changes in p53 protein expression led to
a corresponding increase of p53 function in the revertants. It
has been reported that wild-type p53 protein binds to de-
fined DNA sequences with high affinity and specificity (22).
To assay p53 transcriptional transactivation activity, we per-
formed transient transfection assays using p53-responsive
reporter constructs. The results from three independent ex-
periments normalized for differences in transfection efficien-
Fig. 4. Steady-state levels of E6-AP mRNA are unchanged, whereas the
levels of E6-AP protein are increased in both revertants compared with
HeLa cells. A, Northern blot analysis of total RNA extracted from HeLa,
HA, and HF. The filter was probed with
32P-labeled E6-AP cDNA. B,
ethidium bromide-stained membrane used for E6-AP mRNA detection. C,
Western blot analysis of cellular lysates probed with anti-E6-AP polyclonal
antibody.
Fig. 5. Induction of p53 by DNA damage is faster and leads to higher p53
levels in the revertants (HA and HF) than in HeLa cells. Cells were induced
with 0.45 nM of actinomycin D (ACTD) for 0, 12, and 24 h before lysis.
Western blot analyses were performed using 25 mg of total cell lysate and
probed with an anti-p53-specific antibody (DO-1). FS-4-human foreskin
fibroblasts and Saos-2 cells were used as a positive and negative control
for p53 induction, respectively.
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of the pMG15 construct, which harbors mutant p53 consen-
sus binding sites, were at the background level in all three
cell lines. When wild-type pG13CAT construct was used, p53
transactivation activity in the parental HeLa cells was also at
the level of background. By contrast, HA and HF revertants
demonstrated, respectively, 25- and 30-fold higher levels of
CAT activity than those detected in HeLa cells. These results
demonstrated that the elevated levels of p53 protein in the
revertants resulted in elevated p53-specific transactivation
of an exogenous, p53-responsive promoter.
Inducible p21
waf-1 Expression in the Revertants but not
in HeLa Cells. We next asked whether the increased p53
proteins levels expressed in the revertants in response to
DNA damage were also functional in the transactivation of
endogenous target genes. The induction of p21
waf-1 gene by
wild-type p53 is mediated by direct binding of the p53 tet-
ramer to the consensus sequence present in the p21
waf-1
promoter (23). Northern blot analysis demonstrated that 5 h
after exposure to g-irradiation, p21
waf-1 mRNA transcription
was induced in the revertants but not in HeLa cells (Fig. 7).
The level of induction of p21
waf-1 mRNA by DNA damage in
revertants was ;4–5-fold. However, the increased mRNA
levels did not give rise to a corresponding increase in
p21
waf-1 protein levels for up to 24 h after cell irradiation or
actinomycin D treatment (not shown). Inducibility of p21
waf-1
mRNA but not protein by g-irradiation indicated that the
wild-type p53 protein induced in the revertants was only
partially functional in vivo.
G1 Arrest Is Abrogated in HeLa Cells and Revertants. A
number of studies demonstrated that exposure of cells with
wild-type p53 and p21
waf-1 to DNA-damaging agents elicits
growth arrest in the G1 phase of the cell cycle (10). The
observed failure of DNA-damaging agents to induce p21
waf-1
protein in the revertant cells predicts that the latter cells
should not undergo G1 arrest after the exposure to DNA-
damaging agents. We therefore performed cell cycle analysis
after treatment with actinomycin D or irradiation. The results
from at least three independent experiments, presented as a
ratio of the number of cells in G1 to S phase (G1-S), are
shown in Fig. 8A. As expected, treatment of human foreskin
fibroblasts with actinomycin D increased the G1-S ratio ;5-
fold, reflecting efficient G1 arrest in these HPV-free control
cells. In untreated cells, the G1-S ratio was very similar,
suggesting that HeLa and revertants do not have differences
in cell cycle distribution. The data in Fig. 5 had indicated that
exposure of HeLa cells to actinomycin D resulted in only a
small and transient increase in p53 protein levels. It was
therefore not surprising that actinomycin D did not alter the
G1-S ratio significantly in HeLa cells. As predicted from the
inability to induce p21
waf-1 protein, we also failed to detect
G1 arrest in both revertants after actinomycin D treatment.
Similar results were obtained using BrdUrd incorporation
(not shown). Thus, despite the elevated steady-state levels of
p53 and the inducibility of p53 protein in the revertants,
actinomycin D treatment failed to arrest cells in the G1 phase
of cell cycle.
To demonstrate that the inability of the HeLa cells and the
revertants to arrest in G1 after DNA damage was independ-
ent of p53 protein levels, cells were treated with L-mimosine,
a p53-independent inducer of p21
waf-1 (24). As control cells,
we used the BICR-M1Rk rat mammary tumor cell line (25),
which has lost the capability to induce p53 and p21
waf-1 and
G1 arrest in response to DNA damage signals induced by
actinomycin D treatment.
6 However, these cells retained the
capacity for p53-independent induction of p21
waf-1 and G1
arrest in response to L-mimosine treatment (Fig. 8B). By
contrast, neither the HeLa cells nor the revertants were able
to respond to L-mimosine treatment by inducing a G1 arrest,
despite the fact that L-mimosine induced p21
waf-1 protein
expression (Fig. 9). Lack of a p21
waf-1-induced G1 arrest in
HeLa suggested the disruption of effector pathways down-
stream of p21
waf-1 in HeLa cells that remains functionally
inactive in the revertants. Taken together, our results indicate
that the p21
waf-1 cell cycle regulatory-dependent pathway
6 A. Mikheev and H. Zarbl, unpublished observations.
Fig. 6. Comparison of p53-induced transcriptional transactivation activ-
ity in revertants and in HeLa cells using reporter constructs harboring
multiple p53 wild-type (pG13CAT) or mutant (-MG15CAT) consensus
binding sequences. Promoter activities were assessed by measuring the
rate of CAT conversion in lysates prepared from 5 3 10
6 cells transiently
transfected with 10 mg of pG13CAT or pMG15CAT. No DNA, background
CAT conversion rates determined in lysates from cells that were electro-
pulsed in the absence of DNA. CAT values are normalized by transfection
efficiency as described by Bahramian and Zarbl (33). M, no DNA; o,
pMG15CAT; u, pG13CAT.
Fig. 7. Induction of p21
waf-1 mRNA transcription in HeLa cells and re-
vertants after g-irradiation. Total mRNA (15 mg) from HeLa, HA, and HF
exposed to 0 or 5 Gy of g-irradiation were separated in agarose gel
containing formaldehyde, transferred to nylon membranes, and hybridized
to [
32P]dCTP-labeled p21
waf-1 cDNA probe. B, ethidium bromide staining
of the Northern blot.
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from HPV-induced transformation.
Discussion
We reported previously the isolation and characterization of
two independent, nontransformed, nontumorigenic revertant
clones of the HeLa cervical cancer cell line that resulted from
the activation of tumor suppressor genes (14). Given that
continuous expression of both the E6 and E7 oncogenes
appears to be necessary for maintenance of both in vitro
transformation and in vivo tumorigenicity of HeLa cervical
carcinoma cells, the simplest explanation for the revertant
phenotypes would be inactivating mutations in the HPV E6 or
E7 oncogenes. However, we have demonstrated that the
levels of both viral oncoproteins were comparable in rever-
tants and parental HeLa cells, and that ectopic expression of
wild-type E6 and E7 failed to retransform either revertant
clone. These results indicated that the revertant phenotypes
did not result from a loss of function mutations in E6 and/or
E7. Our previous study also indicated that the revertant
phenotypes of both the HA and HF clones were dominant in
the cell fusion experiment. These observations were consist-
ent with the hypothesis that the revertants had sustained
activating mutations in one or more tumor suppressor genes.
Alternatively, the revertants could have sustained dominant-
negative mutations in cellular genes that function as essential
effectors of the E6 or E7 pathways, thereby allowing func-
tional reactivation of the wild-type p53 and/or Rb genes.
We observed that a common molecular change distin-
guishing both revertants from the parental transformed HeLa
cell line was an increase in the steady state levels of the p53
tumor suppressor protein. However, Northern blot analyses
revealed no quantitative differences in p53 mRNA expression
among the three cell lines, indicating that increased p53
levels resulted from altered posttranslational regulation in the
revertants. Although the vast majority of stabilizing p53 mu-
tations have been primarily associated with loss of wild-type
p53 function, it was still necessary to rule out the presence of
any p53 mutations in the revertants. RNase protection as-
says on the entire p53 open reading frame and direct se-
quencing of exons 4 to 11 of the p53 cDNA revealed no
mutations in any of the cell lines. It is thus unlikely that the
increased levels of p53 protein in the revertants were attrib-
utable to mutations in the p53 gene.
Our results further showed that increased p53 protein
expression in the revertants was the result of posttrans-
lational regulation. We demonstrated that the half-life of
the p53 protein in the revertants was 4-fold higher than in
the transformed parental cells. Increased stability of p53 in
HA and HF cells could be a result of disruption of the
E6/E6-AP/p53 protein complex, which triggers p53 ubiq-
uitination and degradation. Previous studies showed that
a lack of expression and/or mutations in E6-AP could
affect E6-mediated binding and degradation of p53 (16,
17). Neither revertant was found to harbor mutations
within the region of E6-AP protein sufficient for interaction
with viral E6 and ubiquitination of the p53 protein. We also
failed to detect any significant differences in steady-state
levels E6-AP mRNA among the cell lines. In fact, the
E6-AP protein levels were increased in revertants com-
pared with parental HeLa cells. The latter result suggested
that stabilization of p53 protein in the revertants was not
attributable to limiting amounts of E6-AP. Therefore, sta-
bilization of p53 in the revertants does not appear to result
from mutations affecting the expression or function of p53,
Fig. 9. Induction of p21
waf-1 protein expression in HeLa and revertants
with L-mimosine. Cells were treated with 250 mML -mimosine and har-
vested 24 h later. Extracted proteins were loaded on 15% SDS-PAGE and
subjected to Western blot analysis. The p21
waf-1 protein was detected
with a p21
waf-1 specific antibody and a horseradish peroxidase-conju-
gated secondary antibody.
Fig. 8. Actinomycin D (Act. D) and L-mimosine failed to induce G1 arrest
in HeLa and revertants. Unsynchronized cells were treated with actino-
mycin D (A)o rL-mimosine (B) for 24 h at a concentration of 1 nM and 250
mM, respectively. Cell cycle analysis was performed as described in “Ma-
terials and Methods.” Fibroblasts and the BICR mammary carcinoma cell
line were used as positive controls for actinomycin D and L-mimosine
treatments, respectively.
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tial posttranslational modification of one or more of these
proteins that lead to the disruption of E6/E6-AP/p53 com-
plex in the revertants. Such a mechanism would lead to
accumulation of the E6-AP, which might otherwise be
degraded along with p53.
To determine whether the interaction E6 with p53 was
altered in the revertants, we used a combination of immu-
noaffinity purification and immunoblotting to detect p53-E6
protein complex formation in the HeLa cells. We found sim-
ilar levels of E6 protein levels in HeLa and revertant cells
using immunoprecipitation and Western blot. Immunaffinity
purification from 10 and 20 mg of total protein allowed de-
tection of an Mr 18,000 band in HeLa cell that was not
detected in revertants or Saos-2 cells. These results pro-
vided evidence for reduced E6 binding to p53 in both rever-
tants.
We next investigated whether the increased p53 protein
levels in HA and HF revertants also results in elevated wild-
type p53 activity. We characterized the revertants for func-
tions that indicate the presence of a functional, wild-type p53
protein including: (a) p53 stabilization in response to DNA
damage; (b) transactivation of promoter construct in tran-
sient transfection assay; (c) transactivation of endogenous
p53 target genes; and (d)G 1 arrest in response to DNA
damage.
Exposure of cells to DNA-damaging agents such as UV
and g-irradiation or actinomycin D has been shown to induce
p53 protein levels and cell cycle arrest in cells that express a
wild-type p53 gene. The resulting increase in p53 protein
levels has also been shown to enhance the DNA binding
affinity of the wild-type protein to its specific binding sites
(22, 23). In the present study, exposure to actinomycin D
(Fig. 5) or g-irradiation (not shown) invariably resulted in the
induction of p53 protein in the revertants and HeLa cells,
indicating the presence of normal p53 in all of the cells.
Exposure to the DNA-damaging agent produced p53 protein
levels that were 5–10 times higher in the revertants than in
the parental HeLa cells. Induction of p53 protein in revertants
was attributable to altered posttranslational modification of
the protein in the revertants, because no significant stimula-
tion of p53 mRNA level was observed for up to 24 h after
actinomycin D treatment in any of the cell lines. In transient
transfection assays, we compared the activities of p53-
responsive reporter constructs that are frequently used to
screen cells for loss or gain of function mutations in the p53
gene. Consistent with the presence of wild-type p53, our
assays revealed that p53 transactivating activities in HA and
HF were, respectively, 30- and 20-fold higher than in HeLa
cells.
To determine whether the elevated wild-type p53 transac-
tivation function contributed to the phenotype of the rever-
tants, we next the assessed p21
waf-1 mRNA levels in HeLa
cells and the revertants before and after DNA damage. The
p21
waf-1 gene was first identified by its differential induction
by wild-type but not by mutant p53. The p53-dependent
induction of waf-1 gene expression after treatment with g-
irradiation in cells with normal p53 is well documented (23).
The p21 gene product was subsequently found to encode an
inhibitor of cyclin-dependent kinase complexes (26), thus
implicating wild-type p53 function in cell cycle control. We
found that p21
waf-1 mRNA was inducible in both revertants
but not in HeLa cells, confirming that there is reactivation of
wild-type p53-dependent transcription in revertants. How-
ever, the levels of p21
waf-1 protein were not increased in
untreated or treated revertant cells. One possible explana-
tion for these observations is that stabilization of p21
waf-1
mRNA may be necessary for its efficient translation. Con-
sistent with such an interpretation, the results of control
experiments indicated that treatment of HPV-free cells with
actinomycin D resulted in a .20-fold increase of p21
waf-1
mRNA, whereas only a 4–5-fold increase was detectable in
the revertants (not shown).
To investigate whether disruption of the p21
waf-1 path-
way contributed to the phenotype of the HA or HF rever-
tants, we treated cells with L-mimosine, a p53-indepen-
dent inducer of p21
waf-1 that also results in stabilizes
p21
waf-1 mRNA (24). Despite the efficient induction of
p21
waf-1 in L-mimosine-treated revertants, the latter also
failed to arrest in the G1 phase of the cell cycle. One
interpretation of these findings is that HeLa cells lack
downstream effector pathways for p21
waf-1-mediated G1
cell cycle arrest. Consistent with such a model, recent
studies have shown that the HPV E7 oncogene, which
inactivates the Rb protein in HeLa cells, can abrogate the
DNA damage-induced checkpoint (27). Thus, functional
inactivation of Rb could be responsible for the inability of
p21
waf-1 to induce G1 arrest in the revertants. This con-
clusion is consistent with the key role of Rb protein in
p53-dependent G1 arrest found in fibroblasts (28). Alter-
natively, the failure to induce G1 arrest could result from
the ability of the E7 oncoprotein to prevent p21
waf-1-me-
diated inhibition of CDK2/cyclin E activity and proliferating
cell nuclear antigen-dependent DNA replication (29). Con-
sistent with the latter interpretation are the results of stud-
ies showing that L-mimosine does not prevent accumula-
tion of cyclin A in HeLa cells (30) and that cells can be
arrested by L-mimosine once they enter S phase (31). A
prediction from this model is that the HPV E7 viral onco-
protein remains active in revertants. It is therefore likely
that the failure of HeLa cells and the revertants to arrest
cells in G1 p53-independent induction of p21
waf-1 by L-
mimosine is caused by an active E7 oncogene.
In conclusion, molecular characterization of revertants
obtained from HeLa cells revealed stabilization of p53
compared with the parental cell line. Stabilization of p53
protein is a result of reduced interaction of p53 and E6.
Induction of p53 protein and p21
waf-1 mRNA after DNA
damage suggested at least partial activation of transacti-
vating properties of p53. Previous studies have suggested
that stabilization of p53 by antisense oligonucleotides (18)
or dominant-negative mutants of E6-AP (17) might provide
effective gene therapy for cervical carcinoma. The results
of the present study indicate that that stabilization of p53
is insufficient to induce cell cycle arrest or inhibit HPV-
induced transformation.
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Cell Culture. HeLa CCL2, HA, HF, FS4, BICR-M1Rk, and Saos-2 cells
(American Type Culture Collection, Rockville, MD) were grown in DMEM
or MEM supplemented with 10% calf serum (Hyclone, Logan, UT) or with
10% Nu Serum (Becton Dickinson, Franklin Lakes, NJ). Cells were grown
to 50%–80% confluence prior to treatment with actinomycin D (Sigma
Chemical Co., St. Louis, MO) or exposure to a single dose of g-irradiation.
Cells were harvested at appropriate time intervals after treatment as
noted.
Plasmids. The pG13CAT and pMG15CAT used in CAT assays were
kindly provided by Dr. Bert Vogelstein. Briefly, both reporter constructs
contain the CAT reporter gene under the control of basal promoters with
13 repeats of the p53 consensus binding site and 15 repeats of a mutated
consensus site, respectively. To generate plasmid pSP73-p53-B/S used
in RNase protection assays, a 1300-bp BamHI/SmaI fragment containing
the entire wild-type p53 open reading frame DNA sequences was sub-
cloned from pC53-SN3 (provided by Dr. Bert Vogelstein, Johns Hopkins
University, Baltimore, MD) into the pSP73 vector (Promega Corp., Madi-
son, WI). A plasmid from Ambion, Inc., carrying a proprietary mutant p53
sequence, was used to generate a control RNA probe.
Western Blotting. E6-AP polyclonal antibody was kindly provided by
Dr. P. Beer-Romero, Mitotix, Inc., Cambridge, MA (18). For p53 detection,
the primary antibody was DO-1 (Santa Cruz Biotechnology, Santa Cruz,
CA). For immunoprecipitation and Western blot detection of E6 protein,
monoclonal antibody C1 3 1 and C1P5 (Santa Cruz Biotechnology),
respectively, were used. As the secondary antibody, horseradish perox-
idase conjugated antimouse and antirabbit antibodies (Transduction Lab-
oratories, Lexington, KY) were used as appropriate.
For Western blotting, protein samples were boiled in sample buffer
prior to loading on a Laemmli gel. SDS-PAGE was carried out in a
Tris-glycine buffer system under constant voltage. Separated proteins
were transferred overnight on a polyvinylidene difluoride membrane (Im-
mobilon-P; Millipore, Bedford, MA) in the cold, under constant voltage of
30–60V, in 25 mM Tris, 190 mM glycine, and 20% methanol. Blotted
membranes were blocked in TBS-T (20 mM Tris, 137 mM NaCl, and 0.1%
Tween 20, pH 7.6) with 5% milk (Blotto) for 30 min and then incubated with
the appropriate antibody dilution in Blotto for 1 h and 15 min at room
temperature. Blots were then washed with TBS-T and incubated with
secondary antibody at 1:4000 dilution in Blotto for 45 min. Blotted anti-
gens were detected using chemoluminescence detection (DuPont NEN,
Boston, MA). Protein standards (Bio-Rad, Hercules, CA) were used. The
quality of transfer was assessed by staining with Coomassie Brilliant Blue
G (Sigma).
Northern Blots. RNA was isolated by the acid phenol method (32).
Aliquots of 20 mg of total mRNA were separated through a 1.2% agarose
gel containing 6% formaldehyde. The RNA was transferred to nylon
membrane (Hybond N; Amersham, Arlington, IL) by blotting in 25 mM
phosphate buffer (pH 6.5) at 1 Amp for 2 h and fixed by UV irradiation.
Blots were prehybridized with calf thymus DNA in 50% formamide, 1 M
NaCl, 0.5% SDS for1ha t4 2
oC before overnight hybridization to radio-
labeled probes corresponding to p21
waf-1, E6-AP, or p53 cDNAs. The
cDNA probes were labeled with [
32P]dCTP (3000 Ci/mmol; DuPont NEN,
Boston, MA) using standard random priming method. Membranes were
washed in 0.1 M NaCl, 0.1% SDS at 65
oC and subjected to autoradiog-
raphy. To control for loading and blotting variations, gels were stained with
ethidium bromide and photographed.
cDNA Sequencing. Poly(A)1 mRNA from HeLa, HA, and HF was
isolated on poly dT resin (Amersham, Arlington, IL) after acid extraction.
Exons 4 to 11 were amplified by reverse transcription-PCR, using the
Ambion p53 mutation detection kit according to the manufacturer’s pro-
tocol (Ambion, Inc.). Multiple clones were subcloned into the plasmid pCR
(Stratagene, La Jolla, CA). Both strands of seven cDNA clones from each
of HeLa, HA, and HF were subjected to sequencing and compared with
wild-type p53 sequences. The region from amino acids 280 to 865 of
E6-AP was also subjected to sequencing. The following overlapping prim-
ers were used to amplify corresponding fragments of E6-AP from cDNA:
primer 1, 59-CTGCTGCTGCTATGGAAGAAGAC-39; primer 2, 59-GGAAA-
CACCTCCCTCATCAACTC-39; primer 3, 59-CTTGAAGAAGCAGTTGTAT-
GTG-39; primer 4, 59-GATCATACATCATTGGGTTACC-39; primer 5, 59-
GAATGTGGAAGATGACATG-39; primer 6, 59-CTGTGCCCGTTGTAA-
ACTGC-39; primer 7, 59-GAAATCGTTCATTCATTTAC-39; and primer 8,
59-TTACAGCATGCCAAATCC-39. All sequencing reactions were per-
formed at a core sequencing laboratory on an ABI Prizm Sequencer.
RNase Protection Assay. An RNase protection assay was used for
the detection of mutations within the p53 cDNA sequences. Plasmid
pSP73-p53-B/S was linearized with HindIII, and a labeled antisense
strand was synthesized from the T7 RNase polymerase promoter. The
assay was performed using an RNase protection kit (Ambion, Inc.) ac-
cording to the manufacturer’s protocol. A second probe, synthesized from
proprietary plasmid and carrying a mutant p53 sequence, was used as a
positive control for mutation detection. A b-actin probe, synthesized with
T7 polymerase from HindIII-linearized pBH-11, was used as an internal
control. Riboprobes were labeled with [a-
32P]UTP at 15 Ci/mmol (DuPont
NEN). Ten mg of total RNA were hybridized with wild-type or mutant p53
probe and with the b-actin control probe in the same reaction tube. The
samples were digested with RNase A and RNase T1, and the protected
fragments were separated in a 5% denaturing polyacrylamide gel. The gel
was then dried and exposed to Kodak X-AR film.
CAT Assays. Approximately 5 3 10
6 cells were transiently transfected
by electroporation with 10 mg of pG13CAT or pMG15CAT or subjected to
pulse in the absence of DNA. The pG13CAT and pMG15CAT reporter
constructs are comprised of the polyoma virus early promoter and the
CAT gene positioned downstream of 13 wild-type or 15 mutated repeats
of a p53 binding sequence, respectively. Electroporation was carried out
at room temperature in culture medium at 270 mV/cm
2 (Gene Pulser;
Bio-Rad, Hercules, CA). Cell lysates were prepared 48 h after transfection,
and a continuous enzymatic assay was carried out over a time course of
3 h to quantitate CAT activity. Linear curves of CAT activity over time were
plotted, and relative CAT activity rates were calculated using the Cricket
Graph software. Half of each cell sample was used in a PCR-based assay
to normalize for transfection efficiency between samples, as described
previously in Bahramian and Zarbl (33).
p53 Half-Life Determination. Subconfluent cell culture (2–4 3 10
6)
cells were incubated overnight in DMEM supplemented with 10% calf
serum. Cells were treated with CHX (20 mg/ml) for 15, 30, 50, or 60 min.
Cells were washed with ice-cold PBS and lysed in RIPA buffer on ice for
30 min. Cell lysates were centrifuged, and equal amounts of protein were
subjected to Western blotting. The p53 protein was quantitated using NIH
Image software and plotted as a percentage of p53 remaining. The aver-
age of three experiments was used to calculate the half-life of the p53 by
regression analysis (Santa Cruz Biotechnology, Santa Cruz, CA).
Cell Cycle Analysis. Unsinchronized cells, 70–80% confluent, were
treated with 1 nM of actinomycin D or 250 mML -mimosine (Sigma). In 24 h,
cells were trypsinized and fixed in 35% ethanol, stained with propidium
iodide, and then analyzed on a Becton Dickinson flow cytometer. In some
experiments after 20 h of actinomycin D treatment or a single dose of
irradiation (6 Gy), cells were labeled with 40 mM BrdUrd (Sigma) for an
additional 4 h. Incorporation of BrdUrd were detected with anti-BrdUrd
antibody conjugated with FITC (Caltag, San Francisco, CA). Cells incor-
porating BrdUrd were detected and analyzed on a Becton Dickinson flow
cytometer.
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